Clinical trial
Avelumab in G2-3 NET
NCT03278379 · Sunnybrook Health Sciences Centre, Other · Completed
Key facts
| NCT number | NCT03278379 |
|---|---|
| Title | Avelumab in G2-3 NET |
| Official title | A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors |
| Acronym | NET-002 |
| Lead sponsor | Sunnybrook Health Sciences Centre, Other |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Avelumab |
| Enrollment | 17 |
| Start date | Nov 15, 2017 |
| Primary completion | Jul 26, 2021 |
| Completion | Jul 6, 2023 |
| First posted | Sep 11, 2017 |
| Last update posted | Dec 24, 2024 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: